Past A Bumpy Road, Ranbaxy Eyes Smooth Path If Exclusive Launches Materialize
This article was originally published in PharmAsia News
Executive Summary
Analysts are re-rating Ranbaxy based on large launch opportunities and a hardening of the base business.